Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Liquid biopsies that analyze circulating tumor DNA (ctDNA) hold great promise in the guidance of clinical treatment for various cancers. However, the innate characteristics of ctDNA make it a difficult target: ctDNA is highly fragmented, and found at very low concentrations, both in absolute terms and relative to wildtype species. Clinically relevant target sequences often differ from the wildtype species by a single DNA base pair. These characteristics make analyzing mutant ctDNA a uniquely difficult process. Despite this, techniques have recently emerged for analyzing ctDNA, and have been used in pilot studies that showed promising results. These techniques each have various drawbacks, either in their analytical capabilities or in practical considerations, which restrict their application to many clinical situations. Many of the most promising potential applications of ctDNA require assay characteristics that are not currently available, and new techniques with these properties could have benefits in companion diagnostics, monitoring response to treatment and early detection. Here we review the current state of the art in ctDNA detection, with critical comparison of the analytical techniques themselves. We also examine the improvements required to expand ctDNA diagnostics to more advanced applications and discuss the most likely pathways for these improvements.

Original languageEnglish
Pages (from-to)540-560
Number of pages21
JournalACS Sensors
Volume3
Issue number3
DOIs
Publication statusPublished - 23 Mar 2018

Keywords

  • assay development
  • cancer
  • cell-free DNA
  • circulating tumor DNA
  • liquid biopsy
  • multiplex
  • sample-limited
  • sensitivity
  • specificity

Cite this

@article{3a39fe8b394241e3b03cb764c9ef2b7d,
title = "Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges",
abstract = "Liquid biopsies that analyze circulating tumor DNA (ctDNA) hold great promise in the guidance of clinical treatment for various cancers. However, the innate characteristics of ctDNA make it a difficult target: ctDNA is highly fragmented, and found at very low concentrations, both in absolute terms and relative to wildtype species. Clinically relevant target sequences often differ from the wildtype species by a single DNA base pair. These characteristics make analyzing mutant ctDNA a uniquely difficult process. Despite this, techniques have recently emerged for analyzing ctDNA, and have been used in pilot studies that showed promising results. These techniques each have various drawbacks, either in their analytical capabilities or in practical considerations, which restrict their application to many clinical situations. Many of the most promising potential applications of ctDNA require assay characteristics that are not currently available, and new techniques with these properties could have benefits in companion diagnostics, monitoring response to treatment and early detection. Here we review the current state of the art in ctDNA detection, with critical comparison of the analytical techniques themselves. We also examine the improvements required to expand ctDNA diagnostics to more advanced applications and discuss the most likely pathways for these improvements.",
keywords = "assay development, cancer, cell-free DNA, circulating tumor DNA, liquid biopsy, multiplex, sample-limited, sensitivity, specificity",
author = "Rodda, {Andrew E.} and Parker, {Bradyn J.} and Andrew Spencer and Corrie, {Simon R.}",
year = "2018",
month = "3",
day = "23",
doi = "10.1021/acssensors.7b00953",
language = "English",
volume = "3",
pages = "540--560",
journal = "ACS Sensors",
issn = "2379-3694",
publisher = "American Chemical Society (ACS)",
number = "3",

}

Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations : Techniques and Challenges. / Rodda, Andrew E.; Parker, Bradyn J.; Spencer, Andrew; Corrie, Simon R.

In: ACS Sensors, Vol. 3, No. 3, 23.03.2018, p. 540-560.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations

T2 - Techniques and Challenges

AU - Rodda, Andrew E.

AU - Parker, Bradyn J.

AU - Spencer, Andrew

AU - Corrie, Simon R.

PY - 2018/3/23

Y1 - 2018/3/23

N2 - Liquid biopsies that analyze circulating tumor DNA (ctDNA) hold great promise in the guidance of clinical treatment for various cancers. However, the innate characteristics of ctDNA make it a difficult target: ctDNA is highly fragmented, and found at very low concentrations, both in absolute terms and relative to wildtype species. Clinically relevant target sequences often differ from the wildtype species by a single DNA base pair. These characteristics make analyzing mutant ctDNA a uniquely difficult process. Despite this, techniques have recently emerged for analyzing ctDNA, and have been used in pilot studies that showed promising results. These techniques each have various drawbacks, either in their analytical capabilities or in practical considerations, which restrict their application to many clinical situations. Many of the most promising potential applications of ctDNA require assay characteristics that are not currently available, and new techniques with these properties could have benefits in companion diagnostics, monitoring response to treatment and early detection. Here we review the current state of the art in ctDNA detection, with critical comparison of the analytical techniques themselves. We also examine the improvements required to expand ctDNA diagnostics to more advanced applications and discuss the most likely pathways for these improvements.

AB - Liquid biopsies that analyze circulating tumor DNA (ctDNA) hold great promise in the guidance of clinical treatment for various cancers. However, the innate characteristics of ctDNA make it a difficult target: ctDNA is highly fragmented, and found at very low concentrations, both in absolute terms and relative to wildtype species. Clinically relevant target sequences often differ from the wildtype species by a single DNA base pair. These characteristics make analyzing mutant ctDNA a uniquely difficult process. Despite this, techniques have recently emerged for analyzing ctDNA, and have been used in pilot studies that showed promising results. These techniques each have various drawbacks, either in their analytical capabilities or in practical considerations, which restrict their application to many clinical situations. Many of the most promising potential applications of ctDNA require assay characteristics that are not currently available, and new techniques with these properties could have benefits in companion diagnostics, monitoring response to treatment and early detection. Here we review the current state of the art in ctDNA detection, with critical comparison of the analytical techniques themselves. We also examine the improvements required to expand ctDNA diagnostics to more advanced applications and discuss the most likely pathways for these improvements.

KW - assay development

KW - cancer

KW - cell-free DNA

KW - circulating tumor DNA

KW - liquid biopsy

KW - multiplex

KW - sample-limited

KW - sensitivity

KW - specificity

UR - http://www.scopus.com/inward/record.url?scp=85044430178&partnerID=8YFLogxK

U2 - 10.1021/acssensors.7b00953

DO - 10.1021/acssensors.7b00953

M3 - Review Article

VL - 3

SP - 540

EP - 560

JO - ACS Sensors

JF - ACS Sensors

SN - 2379-3694

IS - 3

ER -